Celemics, Inc.
Financials
Valuation Metrics
Celemics, Inc.'s Market Cap is ₩1057B. At end of 2025 it was ₩304B. Ranked #1194 of 2,436 in KR market (top 49%), #630 of 1,649 on KOSDAQ (top 38%), #138 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 59%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 105.67B KRW | KR#1,194/2,436 Sec#138/234 |
| Revenue | 4.97B KRW | KR#2,345/2,436 Sec#196/234 |
| Net Income | -7.84B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 22.87B KRW | KR#2,354/2,436 Sec#227/234 |
| Net Assets | 17.50B KRW | KR#2,308/2,436 Sec#217/234 |
| Employees | 42 | KR#2,093/2,436 Sec#192/234 |
| Value | ||
| P/B | 6.04x | KR#2,283/2,436 Sec#192/234 |
| P/S | 21.27x | KR#2,338/2,436 Sec#185/234 |
| FCF Yield | -3.56% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -44.77% | KR#2,251/2,436 Sec#194/234 |
| ROA | -34.27% | KR#2,325/2,436 Sec#209/234 |
| Op. Margin | -86.61% | KR#2,301/2,436 Sec#172/234 |
| Revenue Growth | -46.39% | KR#2,268/2,436 Sec#202/234 |
| Financial Health | ||
| Debt Ratio | 130.65% | KR#865/2,436 Sec#98/234 |
| Total Debt | 3.47B KRW | KR#1,841/2,436 Sec#178/234 |
| FCF | -3.76B KRW | KR#1,440/2,436 Sec#113/234 |
| Cash | 6.66B KRW | KR#1,879/2,436 Sec#165/234 |
| Current Ratio | 6.65x | KR#194/2,436 Sec#44/234 |
| Performance | ||
| 1Y Return | 197.17% | KR#45/2,436 Sec#3/234 |
| 1M Return | -17.68% | KR#1,998/2,436 Sec#191/234 |
| From 52W High | -52.37% | KR#1,242/2,436 Sec#108/234 |
| 1Y MDD | -50.27% | KR#950/2,436 Sec#80/234 |
| Trading | ||
| Volume | 46,455 shares | KR#1,373/2,436 Sec#135/234 |
| Foreign Own. | 1.06% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -960 KRW | KR—/2,436 Sec—/234 |
| BPS | 2,144 KRW | KR#1,992/2,436 Sec#164/234 |
Company Info
CeleMix was established in 2010 to manufacture and analyze basic pharmaceutical substances and biological preparations, and was specially listed on the KOSDAQ market in 2020 as a technology growth company. This venture company specializes as an NGS-based gene analysis technology platform, producing and selling MSSIC-based Target Capture Kits and BTSeq sequencing solutions. It develops DNA-related cloning technologies through technology convergence across biotechnology, nanotechnology, and information technology, supplying essential materials to various sectors. CeleMix is headquartered in Geumcheon-gu, Seoul.